Authors
Latest:
Highlighting the Efficacy of VaxEffect With Immune Response to COVID-19 VaccinesRenold Capocasale and Grant Morgan, PhD, PMP, both of FlowMetric Life Sciences, Inc., discuss the vaccination immune response monitoring platform VaxEffect and its clinical application, as well as potential next steps for immune response tests with other vaccines aside from COVID-19.
Latest:
Dr Hill on Efficacy of Dostarlimab in dMMR Locally Advanced Rectal CancerJoshua Hill, MD, MS, discussed the early efficacy of dostarlimab in mismatch repair–deficient locally advanced rectal cancer.
Latest:
Las Implicaciones del Estudo VIALE-A de Venetoclax Mas Azacitidina Para Paciente Inelegibles a Quimioterapia IntensivaNidia Zapata, MD, discusses the role of triplet therapy in the treatment of patients with acute myeloid leukemia.
Latest:
Dr Possik on the Importance of Diversity and Equity in Melanoma ResearchPatricia A. Possik, PhD, discusses the importance of efforts to improve diversity, equity, and inclusion in melanoma research.
Latest:
Looking at Novel Treatments in Lung and Genitourinary Cancers From ESMO 2023: Drs Janne and BastosOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Latest:
Dr Stockhammer on Gene Alterations and Poor Outcomes in EGFR-Mutant Lung CancerPaul Stockhammer, MD, PhD, discusses research into the association between alterations in multiple tumor suppressor genes and poorer outcomes in patients with EGFR-mutant lung cancer, which was presented at the 2023 ASCO Annual Meeting.
Latest:
Dr Zeidan on Classification and Treatment Updates in MDSAmer Zeidan, MBBS, discusses classification and treatment updates for patients with myelodysplastic syndrome.
Latest:
Dr Lin on Defining Biomarker-Based Treatment Approaches in NSCLCEdwin Lin, MD, PhD, discusses the utilization of antibody-drug conjugates and the importance of defining biomarker-based approaches for this treatment class in patients with non–small cell lung cancer.
Latest:
Dr Miron on the Methods of Examining Molecular Alterations in Intraductal Carcinoma of the ProstateBenjamin Miron, MD, discusses the methods utilized in a study of molecular alterations in patients with intraductal carcinoma of the prostate and the next steps for this research.
Latest:
Dr. Meyer on Standard Treatment Options in Cardiac AngiosarcomaChristian Frederick Meyer, MD, PhD, MS, discusses standard treatment options in cardiac angiosarcoma.
Latest:
Dr. Choudhri on the Impact of Artificial Intelligence in Cancer CareAjay Choudhri, MD, discusses the impact of developments in artificial intelligence in cancer care.
Latest:
Dr. Narla on Advances Made With Precision Medicine in OncologyGoutham Narla, MD, PhD, discusses advances made with precision medicine in oncology.
Latest:
Dr. Williams on the Role of PI3K Inhibitors in HR+/HER2- Breast CancerNicole O. Williams, MD, discusses the role of PI3K inhibitors in hormone receptor–positive, HER2-negative breast cancer.
Latest:
Dr Matous on the Use Talquetamab/Pomalidomide in Relapsed/Refractory Multiple MyelomaJeffrey Matous, MD, discusses outcomes from the phase 1b MonumenTAL-2 trial with the combination of talquetamab and pomalidomide in patients with relapsed/refractory multiple myeloma.
Latest:
Dr Yap on the Continued Investigation of Saruparib in Advanced Solid TumorsTimothy Yap, MBBS, PhD, FRCP, discusses next steps for investigating saruparib in advanced solid tumors with genetic mutations, including prostate cancer.
Latest:
Dr. Tykodi on the KEYNOTE-427 Trial With Pembrolizumab in RCCScott S. Tykodi, MD, PhD, provides background to the phase 2 KEYNOTE-427 trial with pembrolizumab in renal cell carcinoma.
Latest:
Window of Opportunity Trials Are Needed for Novel Tissue Biomarker Analysis in Head and Neck CancersDrug development is a difficult and ever-changing process, with new agents being developed by industry and academic partners.
Latest:
Future Perspectives in Higher-Risk MDSDr Gustavo Rivero comments on novel treatment combinations and potential new biomarkers in patients with MDS.
Latest:
Dr Hogen on Survival Outcomes With Neoadjuvant Chemotherapy and ICS in Epithelial Ovarian CancerLiat Hogen, MD, FRCSC, discusses the survival outcomes achieved with interval cytoreductive surgery following neoadjuvant chemotherapy in a study of patients with initial unresectable stage IV ovarian cancer.
Latest:
Dr Gluz on the Rationale for the WSG-TP-II Trial in HR+/HER2+ Early Breast CancerOleg Gluz, MD, discusses the rationale for investigating neoadjuvant endocrine therapy plus trastuzumab and pertuzumab in HR+/HER2+ early breast cancer.
Latest:
Concluding Remarks for the Current Use of ctDNA Testing for Treatment Decisions in stage II-III CRCYoshiaki Nakamura, MD, PhD, discusses the quantification threshold for tissue-free ctDNA in detecting residual tumor fractions, highlights additional mutations and hypermethylated loci identified by epigenomic assays, and examines how these assays complement current radiographic monitoring in stage II to III CRC while also considering their evolving role in identifying MRD to enhance recurrence-free survival.
Latest:
Dr. Alistar on the Need to Develop Biomarkers in Pancreatic CancerAngela Tatiana Alistar, MD, discusses the need to develop biomarkers in pancreatic cancer.
Latest:
Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR TumorsDrs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
Latest:
Unmet Needs in SM TreatmentThe panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.
Latest:
LAG-3 Fills a Complex Role in the Immune SystemThe LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.
Latest:
Dr Tan on the Role of Nivolumab/Ipilimumab in Favorable-Risk Advanced RCCAlan Tan, MD, discusses the potential role of nivolumab plus ipilimumab in favorable-risk renal cell carcinoma
Latest:
Dr Koehne on the Use of Chemotherapy-Only Conditioning Regimens in Hematologic MalignanciesGuenther Koehne, MD, PhD, discusses the use of chemotherapy-only conditioning regimens for patients with hematologic malignancies undergoing transplant.
Latest:
Dr. Robesti on Optimizing Patient Selection for Salvage Lymph Node Dissection in Prostate CancerDaniele Robesti, MD, discusses how to optimize patient selection for salvage lymph node dissection in prostate cancer.
Latest:
Dr. Spiess on Key Updates in the Management of Penile CancerPhilippe E. Spiess, MD, MS, FACS, shares key updates in the management of patients with penile cancer.
.jpg?fit=crop&auto=format)
